HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 6, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, will provide a corporate overview at the BIO CEO & Investor Conference, being held February 12-13 at the New York Marriott Marquis Hotel in New York City.

BIO CEO & Investor Conference Presentation Details

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by a higher response to NurOwn® compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTSCorporate: Uri Yablonka Chief Business Officer BrainStorm Cell Therapeutics Inc. Phone: 646-666-3188 [email protected]

Investors: Michael Rice LifeSci Advisors LLC Phone: 646-597-6979 [email protected]

Media: Matt Middleman, M.D.LifeSci Public Relations, LLC Phone: 646-627-8384[email protected]

View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-the-bio-ceo--investor-conference-300594015.html

SOURCE BrainStorm Cell Therapeutics Inc.